In other epithelial and mesenchymal tumor(s), significant CD171 expression was observed in ovary serous carcinoma (87%, Figure 3A), malignant mesothelioma (70%, Figure 3B), testicular embryonal carcinoma (60%), colorectal adenocarcinoma (56%), and alveolar rhabdomyosarcoma (50%, Figure 2A). This evidence concerns the gene L1CAM and alveolar rhabdomyosarcoma.